BIIB
Price
$129.13
Change
+$1.37 (+1.07%)
Updated
Aug 11, 12:15 PM (EDT)
Capitalization
19.16B
72 days until earnings call
NVS
Price
$116.84
Change
+$0.92 (+0.79%)
Updated
Aug 8 closing price
Capitalization
225.96B
78 days until earnings call
Interact to see
Advertisement

BIIB vs NVS

Header iconBIIB vs NVS Comparison
Open Charts BIIB vs NVSBanner chart's image
Biogen
Price$129.13
Change+$1.37 (+1.07%)
Volume$100
Capitalization19.16B
Novartis AG
Price$116.84
Change+$0.92 (+0.79%)
Volume$1.59M
Capitalization225.96B
BIIB vs NVS Comparison Chart in %
Loading...
BIIB
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
NVS
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
View a ticker or compare two or three
VS
BIIB vs. NVS commentary
Aug 11, 2025

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is BIIB is a Hold and NVS is a StrongBuy.

Interact to see
Advertisement
COMPARISON
Comparison
Aug 11, 2025
Stock price -- (BIIB: $127.75 vs. NVS: $116.84)
Brand notoriety: BIIB: Notable vs. NVS: Not notable
Both companies represent the Pharmaceuticals: Major industry
Current volume relative to the 65-day Moving Average: BIIB: 0% vs. NVS: 96%
Market capitalization -- BIIB: $19.16B vs. NVS: $225.96B
BIIB [@Pharmaceuticals: Major] is valued at $19.16B. NVS’s [@Pharmaceuticals: Major] market capitalization is $225.96B. The market cap for tickers in the [@Pharmaceuticals: Major] industry ranges from $560.87B to $0. The average market capitalization across the [@Pharmaceuticals: Major] industry is $85.11B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

BIIB’s FA Score shows that 0 FA rating(s) are green whileNVS’s FA Score has 3 green FA rating(s).

  • BIIB’s FA Score: 0 green, 5 red.
  • NVS’s FA Score: 3 green, 2 red.
According to our system of comparison, NVS is a better buy in the long-term than BIIB.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

BIIB’s TA Score shows that 2 TA indicator(s) are bullish while NVS’s TA Score has 3 bullish TA indicator(s).

  • BIIB’s TA Score: 2 bullish, 6 bearish.
  • NVS’s TA Score: 3 bullish, 7 bearish.
According to our system of comparison, NVS is a better buy in the short-term than BIIB.

Price Growth

BIIB (@Pharmaceuticals: Major) experienced а -3.18% price change this week, while NVS (@Pharmaceuticals: Major) price change was +1.34% for the same time period.

The average weekly price growth across all stocks in the @Pharmaceuticals: Major industry was -1.65%. For the same industry, the average monthly price growth was +3.92%, and the average quarterly price growth was +11.76%.

Reported Earning Dates

BIIB is expected to report earnings on Oct 22, 2025.

NVS is expected to report earnings on Oct 28, 2025.

Industries' Descriptions

@Pharmaceuticals: Major (-1.65% weekly)

The Major Pharmaceuticals industry includes companies that are involved in various processes of creating drugs to treat/prevent diseases. These companies engage in research, testing and manufacturing, as well as the distribution of pharmaceuticals into markets. Johnson & Johnson, Merck & Co., Inc., Pfizer Inc. and Novartis are among the largest companies in this category.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
NVS($226B) has a higher market cap than BIIB($19.2B). NVS has higher P/E ratio than BIIB: NVS (17.03) vs BIIB (12.50). NVS YTD gains are higher at: 24.393 vs. BIIB (-16.460). NVS has higher annual earnings (EBITDA): 22.7B vs. BIIB (2.79B). NVS has more cash in the bank: 7B vs. BIIB (2.76B). BIIB has less debt than NVS: BIIB (6.6B) vs NVS (32.6B). NVS has higher revenues than BIIB: NVS (55.2B) vs BIIB (10B).
BIIBNVSBIIB / NVS
Capitalization19.2B226B8%
EBITDA2.79B22.7B12%
Gain YTD-16.46024.393-67%
P/E Ratio12.5017.0373%
Revenue10B55.2B18%
Total Cash2.76B7B39%
Total Debt6.6B32.6B20%
FUNDAMENTALS RATINGS
BIIB vs NVS: Fundamental Ratings
BIIB
NVS
OUTLOOK RATING
1..100
5050
VALUATION
overvalued / fair valued / undervalued
1..100
90
Overvalued
13
Undervalued
PROFIT vs RISK RATING
1..100
10019
SMR RATING
1..100
7329
PRICE GROWTH RATING
1..100
6152
P/E GROWTH RATING
1..100
9482
SEASONALITY SCORE
1..100
85n/a

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

NVS's Valuation (13) in the Pharmaceuticals Major industry is significantly better than the same rating for BIIB (90) in the Biotechnology industry. This means that NVS’s stock grew significantly faster than BIIB’s over the last 12 months.

NVS's Profit vs Risk Rating (19) in the Pharmaceuticals Major industry is significantly better than the same rating for BIIB (100) in the Biotechnology industry. This means that NVS’s stock grew significantly faster than BIIB’s over the last 12 months.

NVS's SMR Rating (29) in the Pharmaceuticals Major industry is somewhat better than the same rating for BIIB (73) in the Biotechnology industry. This means that NVS’s stock grew somewhat faster than BIIB’s over the last 12 months.

NVS's Price Growth Rating (52) in the Pharmaceuticals Major industry is in the same range as BIIB (61) in the Biotechnology industry. This means that NVS’s stock grew similarly to BIIB’s over the last 12 months.

NVS's P/E Growth Rating (82) in the Pharmaceuticals Major industry is in the same range as BIIB (94) in the Biotechnology industry. This means that NVS’s stock grew similarly to BIIB’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
BIIBNVS
RSI
ODDS (%)
N/A
Bullish Trend 4 days ago
56%
Stochastic
ODDS (%)
Bearish Trend 4 days ago
77%
Bearish Trend 4 days ago
45%
Momentum
ODDS (%)
Bearish Trend 4 days ago
68%
Bearish Trend 4 days ago
47%
MACD
ODDS (%)
Bearish Trend 4 days ago
70%
Bearish Trend 4 days ago
38%
TrendWeek
ODDS (%)
Bearish Trend 4 days ago
71%
Bullish Trend 4 days ago
49%
TrendMonth
ODDS (%)
Bearish Trend 4 days ago
70%
Bearish Trend 4 days ago
40%
Advances
ODDS (%)
Bullish Trend 11 days ago
53%
Bullish Trend 4 days ago
49%
Declines
ODDS (%)
Bearish Trend 13 days ago
70%
Bearish Trend 6 days ago
45%
BollingerBands
ODDS (%)
Bullish Trend 4 days ago
55%
Bullish Trend 4 days ago
51%
Aroon
ODDS (%)
N/A
Bearish Trend 4 days ago
35%
View a ticker or compare two or three
Interact to see
Advertisement
BIIB
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
NVS
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
STOCK / NAMEPrice $Chg $Chg %
DBX26.910.71
+2.71%
Dropbox
FCNCP21.700.13
+0.60%
First Citizens BancShares
RVLV19.64-0.09
-0.46%
Revolve Group
NGNE21.22-0.24
-1.12%
Neurogene
ABLV0.98-0.04
-3.82%
Able View Global

BIIB and

Correlation & Price change

A.I.dvisor indicates that over the last year, BIIB has been loosely correlated with PFE. These tickers have moved in lockstep 53% of the time. This A.I.-generated data suggests there is some statistical probability that if BIIB jumps, then PFE could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To BIIB
1D Price
Change %
BIIB100%
N/A
PFE - BIIB
53%
Loosely correlated
+1.44%
MRK - BIIB
48%
Loosely correlated
+0.40%
NVS - BIIB
45%
Loosely correlated
+0.79%
GSK - BIIB
45%
Loosely correlated
+0.59%
AMGN - BIIB
44%
Loosely correlated
+1.24%
More

NVS and

Correlation & Price change

A.I.dvisor indicates that over the last year, NVS has been closely correlated with GSK. These tickers have moved in lockstep 67% of the time. This A.I.-generated data suggests there is a high statistical probability that if NVS jumps, then GSK could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To NVS
1D Price
Change %
NVS100%
+0.79%
GSK - NVS
67%
Closely correlated
+0.59%
AZN - NVS
60%
Loosely correlated
-0.68%
PFE - NVS
56%
Loosely correlated
+1.44%
JNJ - NVS
55%
Loosely correlated
+1.05%
SNY - NVS
48%
Loosely correlated
-0.63%
More